"Placebo Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
Descriptor ID |
D015990
|
MeSH Number(s) |
N05.715.350.350.625 N06.850.490.734.875
|
Concept/Terms |
Placebo Effect- Placebo Effect
- Effect, Placebo
- Effects, Placebo
- Placebo Effects
|
Below are MeSH descriptors whose meaning is more general than "Placebo Effect".
Below are MeSH descriptors whose meaning is more specific than "Placebo Effect".
This graph shows the total number of publications written about "Placebo Effect" by people in this website by year, and whether "Placebo Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 3 | 3 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 2 | 3 |
2011 | 1 | 4 | 5 |
2012 | 0 | 2 | 2 |
2013 | 1 | 1 | 2 |
2014 | 0 | 2 | 2 |
2016 | 0 | 1 | 1 |
2017 | 1 | 1 | 2 |
2018 | 0 | 1 | 1 |
2019 | 0 | 2 | 2 |
2021 | 0 | 2 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Placebo Effect" by people in Profiles.
-
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838.
-
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021 08 28; 14(1):133.
-
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021 04; 225:108679.
-
Results of the FUEL Trial. Circulation. 2020 02 25; 141(8):641-651.
-
Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019 11; 16(11):e1002960.
-
Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol. 2018 Jun; 38(3):200-206.
-
Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders. Muscle Nerve. 2017 09; 56(3):358-367.
-
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2017 01 06; 18(1):8.
-
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 12 13; 316(22):2373-2384.
-
The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.